原发性或挽救性局部治疗后复发前列腺癌的一线全身治疗:文献系统综述
本系统综述检索2010年1月至2021年12月MEDLINE、EMBASE和ClinicalTrials.gov,纳入40项研究及1项检索后发表的重要研究,评估局部根治性前列腺切除或放疗后复发前列腺癌的一线全身治疗选择与疗效,并按GRADE方法评价质量。
要点
- 转移性复发患者从雄激素 deprivation 治疗(ADT)联合雄激素受体信号抑制剂(ARSI)中获益。
- 多西他赛应保留给传统影像学高肿瘤负荷的转移性复发患者。
- 仅生化复发且具高风险特征(如PSA倍增时间短或血清PSA高)者,从持续或间歇ADT中获益。
核心结论
- 本系统综述总结了局部治疗后复发前列腺癌一线全身治疗的研究发现与推荐。
研究设计与样本
- 按PRISMA指南对2010年1月至2021年12月MEDLINE、EMBASE和ClinicalTrials.gov发表的研究进行系统综述,共40项研究符合纳入标准,另纳入1项检索后发表的重要研究,质量采用GRADE方法评估。
主要发现
- 转移性复发患者从ADT联合雄激素受体信号抑制剂中获益。
- 多西他赛应保留给传统影像学高肿瘤负荷的转移性复发患者。
- 仅生化复发且具高风险特征(如PSA倍增时间短或血清PSA高)的患者从持续或间歇ADT中获益。
关键数值与推荐
- 转移性复发:ADT联合雄激素受体信号抑制剂带来获益。
- 多西他赛:保留用于传统影像学高肿瘤负荷的转移性复发患者。
- 仅生化复发:具高风险特征(PSA倍增时间短或血清PSA高)者从持续或间歇ADT中获益。
局限性
- 已发表文献的当前局限包括未考虑当代正电子发射断层成像(PET)用于评估转移性复发或负荷,以及生活质量评估较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Several studies have investigated selection and sequencing of systemic agents to manage recurrent prostate cancer following local definitive treatment. OBJECTIVE: To define the incidence of recurrent prostate cancer in different countries, and systematically review management options and efficacy of first-line systemic therapies for patients with prostate cancer previously treated with definitive radical prostatectomy or radiation therapy. EVIDENCE ACQUISITION: We performed a systematic review of studies published from January 2010 to December 2021 in MEDLINE, EMBASE, or ClinicalTrials.gov according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Quality was assessed using the Grades of Recommendation, Assessment, Development and Evaluation methodology. The potential regional burdens of recurrent prostate cancer were estimated by analyzing various regional registry data. EVIDENCE SYNTHESIS: A total of 40 studies met the inclusion criteria and an additional landmark study published after the query was included in this review. Patients with metastatic recurrent disease derive benefit from the addition of androgen receptor signaling inhibitors to androgen deprivation therapy, while docetaxel should be reserved for patients with a high-volume metastatic burden by conventional imaging. Patients with biochemical-only recurrent disease benefit from continuous or intermittent androgen deprivation therapy if they possess high-risk features such as short prostate-specific antigen doubling time or high serum prostate-specific antigen. Current limitations to the published literature include no consideration of contemporary positron emission tomography imaging for evaluating metastatic recurrence or burden and few quality of life assessments. CONCLUSIONS: This systematic review summarizes the findings and recommendations for first-line systemic therapy for patients with recurrent prostate cancer following local therapy. PATIENT SUMMARY: We performed a systematic evaluation and summary of all studies published within the past decade on the topic of medications used to treat prostate cancer after it has recurred following radiation therapy or surgery. This review can be used to inform guidelines for prostate cancer management.
引用
- Weiner AB, Siebert AL, Fenton SE, et al. First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. Eur Urol Oncol. 2022. PMID: 35641398. doi:10.1016/j.euo.2022.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。